ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer

The goal of this clinical trial is to compare in resectable colorectal cancer liver metastasis patients.The main question it aims to answer is whether the 3-year progression-free survival rate (PFS) of "watching and waiting" is non-inferior to adjuvant chemotherapy in postoperative ctDNA-negative resectable colorectal cancer liver metastasis patients.Participants will undergo ctDNA testing after resection of colorectal cancer liver metastasis, and will be randomly assigned to receive adjuvant chemotherapy or "watching and waiting" treatment strategy. The researchers will compare the outcomes b

Trial Details

NCT ID
NCT05815082
Phase
PHASE3
Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Colorectal cancer resection combined with liver metastasis resection.
  • FOLFOX chemotherapy regimen
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Both genders are eligible; aged between 18-75 years old; have received neoadjuvant chemotherapy;
  • Patients with liver metastatic colorectal cancer who have achieved R0 resection according to MDT evaluation (including patients with metastases tre…
  • Patients with negative ctDNA after surgery;
  • ASA grade \<IV and/or ECOG performance status score ≤ 2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →